Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1Breast 1

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Breast Neoplasms 2Urogenital Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Unknown Primary 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Fanconi Anemia, Complementation Group D1 1Digestive System Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

olaparib 6talazoparib 1liposomal doxorubicin 1iniparib 1Surveys and Questionnaires 1Secretin 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1Carboplatin 1Biopsy, Fine-Needle 1ABT-767 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fanconi Anemia, Complementation Group D1 × Genetic Counseling × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡